New Mexico Educational Retirement Board reduced its position in shares of Edwards Lifesciences Corporation (NYSE:EW) by 9.7% during the second quarter, according to its most recent 13F filing with the Securities and Exchange Commission. The firm owned 19,460 shares of the medical research company’s stock after selling 2,100 shares during the period. New Mexico Educational Retirement Board’s holdings in Edwards Lifesciences Corporation were worth $2,241,000 as of its most recent filing with the SEC.

Several other hedge funds have also recently made changes to their positions in the stock. Sabal Trust CO increased its stake in shares of Edwards Lifesciences Corporation by 0.5% in the second quarter. Sabal Trust CO now owns 2,934 shares of the medical research company’s stock valued at $347,000 after buying an additional 14 shares during the period. Alexandria Capital LLC increased its stake in Edwards Lifesciences Corporation by 1.7% in the second quarter. Alexandria Capital LLC now owns 1,146 shares of the medical research company’s stock worth $136,000 after buying an additional 19 shares during the period. Quadrant Capital Group LLC increased its stake in Edwards Lifesciences Corporation by 3.5% in the first quarter. Quadrant Capital Group LLC now owns 1,209 shares of the medical research company’s stock worth $109,000 after buying an additional 41 shares during the period. Rehmann Capital Advisory Group increased its stake in Edwards Lifesciences Corporation by 1.6% in the first quarter. Rehmann Capital Advisory Group now owns 3,393 shares of the medical research company’s stock worth $319,000 after buying an additional 55 shares during the period. Finally, M Holdings Securities Inc. increased its stake in Edwards Lifesciences Corporation by 1.5% in the first quarter. M Holdings Securities Inc. now owns 4,132 shares of the medical research company’s stock worth $389,000 after buying an additional 62 shares during the period. Institutional investors and hedge funds own 84.15% of the company’s stock.

Shares of Edwards Lifesciences Corporation (NYSE EW) opened at 114.13 on Friday. The company has a market capitalization of $24.10 billion, a PE ratio of 34.62 and a beta of 0.63. The stock’s 50 day moving average price is $117.06 and its 200 day moving average price is $105.21. Edwards Lifesciences Corporation has a 12-month low of $81.12 and a 12-month high of $121.75.

Edwards Lifesciences Corporation (NYSE:EW) last announced its quarterly earnings data on Wednesday, July 26th. The medical research company reported $1.08 earnings per share for the quarter, beating the Zacks’ consensus estimate of $0.88 by $0.20. The company had revenue of $842 million for the quarter, compared to analysts’ expectations of $839.16 million. Edwards Lifesciences Corporation had a return on equity of 27.17% and a net margin of 22.16%. Edwards Lifesciences Corporation’s revenue for the quarter was up 10.9% compared to the same quarter last year. During the same period last year, the firm posted $0.76 EPS. On average, equities research analysts forecast that Edwards Lifesciences Corporation will post $3.78 earnings per share for the current year.

TRADEMARK VIOLATION WARNING: This piece of content was originally reported by Watch List News and is the property of of Watch List News. If you are reading this piece of content on another website, it was copied illegally and republished in violation of United States and international copyright & trademark law. The original version of this piece of content can be read at https://www.watchlistnews.com/new-mexico-educational-retirement-board-has-2-24-million-position-in-edwards-lifesciences-corporation-nyseew/1473383.html.

A number of analysts have recently issued reports on the stock. BidaskClub downgraded shares of Edwards Lifesciences Corporation from a “strong-buy” rating to a “buy” rating in a report on Tuesday, June 13th. Canaccord Genuity reiterated a “buy” rating and issued a $150.00 price objective on shares of Edwards Lifesciences Corporation in a report on Wednesday, June 28th. Zacks Investment Research upgraded shares of Edwards Lifesciences Corporation from a “hold” rating to a “buy” rating and set a $129.00 price objective on the stock in a report on Thursday, June 1st. Goldman Sachs Group, Inc. (The) assumed coverage on shares of Edwards Lifesciences Corporation in a report on Tuesday, May 16th. They issued a “conviction-buy” rating and a $138.00 price objective on the stock. Finally, Cowen and Company reiterated an “outperform” rating and issued a $135.00 price objective (up from $130.00) on shares of Edwards Lifesciences Corporation in a report on Thursday, July 27th. Five investment analysts have rated the stock with a hold rating, eighteen have assigned a buy rating and one has assigned a strong buy rating to the company. The company currently has an average rating of “Buy” and an average target price of $121.13.

In other news, VP Donald E. Bobo, Jr. sold 25,000 shares of Edwards Lifesciences Corporation stock in a transaction that occurred on Friday, August 4th. The stock was sold at an average price of $116.00, for a total value of $2,900,000.00. The sale was disclosed in a document filed with the SEC, which is available through this link. Also, CEO Michael A. Mussallem sold 32,900 shares of Edwards Lifesciences Corporation stock in a transaction that occurred on Wednesday, June 7th. The stock was sold at an average price of $118.05, for a total value of $3,883,845.00. The disclosure for this sale can be found here. Over the last three months, insiders have sold 183,412 shares of company stock worth $21,176,230. 2.13% of the stock is currently owned by insiders.

Edwards Lifesciences Corporation Company Profile

Edwards Lifesciences Corporation is a manufacturer of heart valve systems and repair products used to replace or repair a patient’s diseased or defective heart valve. The Company is engaged in patient-focused innovations for structural heart disease and critical care monitoring. Its segments include United States, Europe, Japan and Rest of World.

Want to see what other hedge funds are holding EW? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Edwards Lifesciences Corporation (NYSE:EW).

Institutional Ownership by Quarter for Edwards Lifesciences Corporation (NYSE:EW)

Receive News & Ratings for Edwards Lifesciences Corporation Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Edwards Lifesciences Corporation and related companies with Analyst Ratings Network's FREE daily email newsletter.